Raymond James Financial
CLDI icon

Raymond James Financial’s Calidi Biotherapeutics CLDI Stock Holding History

Raymond James Financial’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-162
Closed -$7.15K – 5299
2025
Q2 		$7.15K Buy
+162
New +$12.6K ﹤0.01% 6052

Other funds holding CLDI

HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Raymond James Financial's CLDI Position: Q3 2025 in Review

Raymond James Financial sold out of Calidi Biotherapeutics (CLDI) in Q3 2025, closing a stake of 162 shares — an estimated $7.15K sold.

Raymond James Financial first reported a position in CLDI in Q2 2025 and held it in 1 quarter. The position peaked at $7.15K in Q2 2025. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2025.

  • Raymond James Financial reported no remaining Calidi Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 162 Calidi Biotherapeutics shares in Q3 2025, an estimated $7.15K.
  • Raymond James Financial first reported a position in Calidi Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Calidi Biotherapeutics position peaked at $7.15K in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.